Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4
about
Ultra-rare Disease and Genomics-Driven Precision MedicineMechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary ImmunodeficienciesFlare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma.Genetic Diagnosis Using Whole Exome Sequencing in Common Variable Immunodeficiency.Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.T Regulatory Cell Biology in Health and Disease.Unintended Immunological Consequences of Biologic Therapy.CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.An Update on the Use of Immunomodulators in Primary Immunodeficiencies.Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome.Bacille Calmette–Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010–2017.Increased Risk for Malignancies in 131 Affected Mutation CarriersCytotoxic T-Lymphocyte-Associated Protein 4 Haploinsufficiency-Associated Inflammation Can Occur Independently of T-Cell HyperproliferationImmune Checkpoints as Therapeutic Targets in AutoimmunityThe Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation
P2860
Q26738455-DC70048F-3D20-4F02-AB31-BDBDE34E5D03Q28066193-23EF9DD3-8B12-4C51-A368-002335A5260DQ33782050-D04A6281-3A8B-48BD-AC29-43D11E4CA906Q36995669-36885EB0-A4BB-42BE-939C-D672DDE81940Q38718016-F11FACA9-E9D1-4820-8B84-D78B183EEFC7Q38753362-C9D0ECCB-8979-4C1B-A126-0E65FCCBE96DQ38871098-12C9B2DB-4DD4-4D3D-BA6A-D1CFBD978181Q38897521-5D13317B-3703-4DDB-A36B-35D653B3F42FQ39016299-3AC0D7CB-5BA4-4EF5-A4D3-A96C48583A6EQ39166973-A844F0BC-86A9-4E92-9004-4A9D11715434Q39363726-B51599EF-1A66-4C00-A67E-FB32283E8FA0Q40076704-3FB61E07-0D8F-4BFC-8679-705FCE1EFB26Q40161255-220D0793-161A-4350-8DE3-36D2D61DAB63Q49417955-2B9984E6-BE44-4ACB-BD3F-0F61EB6916D0Q55514852-C55B1303-BA79-4830-9406-27186D2FCF20Q56889015-FD565828-BB2A-4AD2-9220-2E0CCC2DEE59Q56890866-FD2300A3-B76D-4924-B407-D344EDAE51F0Q57817465-F14F2854-4B92-47BF-B232-7C8608D49AF7Q58795403-F5901565-8EE9-40FD-BC10-0219752BFEEC
P2860
Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@ast
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@en
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@nl
type
label
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@ast
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@en
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@nl
prefLabel
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@ast
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@en
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@nl
P2093
P50
P3181
P1476
Abatacept alleviates severe au ...... ng a de novo variant in CTLA-4
@en
P2093
Cho-Rong Lee
Choong Ho Shin
Hyoung Jin Kang
Jae Sung Ko
Jeong Kee Seo
Sangmoon Lee
Solha Hwang
Sun-Mi Baek
Sung Gyoo Park
P304
P3181
P356
10.1016/J.JACI.2015.08.036
P407
P577
2016-01-01T00:00:00Z